Market Newsdesk

TORONTO, Nov. 17, 2020 /CNW/ – TD Asset Management Inc. (“TDAM”) today announced the November cash distributions for the TD Exchange-Traded Funds (the “TD ETFs”) listed below. Unitholders of record on November 27, 2020 will receive cash distributions payable on December 4, 2020.

For more information regarding TD ETFs, visit TDAssetManagement.com

Commissions, management fees and expenses all may be associated with investments in exchange-traded funds (ETFs). Please read the prospectus and summary document(s) before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. ETF units are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns.

The TD Canadian Aggregate Bond Index ETF (the “TD ETF”) is not sponsored, promoted, sold or supported in any other manner by Solactive AG nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index (as defined below) and/or any trade mark(s) associated with the Index or the price of the Index at any time or in any other respect. The Solactive Canadian Select Universe Bond Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Issuer, Solactive AG has no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the TD ETF. Neither publication of the Index by Solactive AG nor the licensing of the Index or any trade mark(s) associated with the Index for the purpose of use in connection with the TD ETF constitutes a recommendation by Solactive AG to invest capital in said TD ETF nor does it in any way represent an assurance or opinion of Solactive AG with regard to any investment in this TD ETF.

TD ETFs are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank.

About TD Asset Management Inc.

TD Asset Management (TDAM), a member of TD Bank Group, is a North American investment management firm. Operating through TD Asset Management Inc. in Canada and TDAM USA Inc. in the U.S., TDAM brings new thinking to investors’ most important challenges. TDAM offers investment solutions to corporations, pension funds, endowments, foundations and individual investors. Additionally, TDAM manages assets on behalf of almost 2 million retail investors and offers a broadly diversified suite of investment solutions including mutual funds, professionally managed portfolios and corporate class funds. Asset management businesses at TD manage $396 billion in assets as at September 30, 2020. Assets under management include TD Asset Management Inc., TDAM USA Inc. and Epoch Investment Partners Inc. (Epoch). All entities are wholly-owned subsidiaries of The Toronto-Dominion Bank.

SOURCE TD Asset Management Inc.

DALLAS, Nov. 17, 2020 /PRNewswire/ — World Series of Golf, Inc. (USOTC: WSGF) (“WSGF”), currently in the process of changing its name to reflect its recently announced new business direction serving short-term rental property owners and investors participating in the sharing economy sector, today announced through its operating subsidiary, Vaycaychella, having completed the development of its peer to peer (P2P) lending application (app).

Vaycaychella has developed a P2P app to connect short term rental property owners and investors within the sharing economy. Vaycaychella’s vision is to empower existing and would-be short-term rental property owners to access investment capital for property acquisitions and improvements financed outside the conventional lending and investment market.

Through Vaycaychella’s P2P app, small business lenders and investors, and even private individuals can connect with entrepreneurial short-term property rental operators to access real estate leveraged investment opportunities not usually available through conventional brokers and agents. 

Likewise, entrepreneurial short-term property rental operators now have access to a wider variety of investment options than ordinarily available through conventional channels.

The impending Airbnb IPO valued at $30 billion exemplifies both the promise of the short-term rental property market in addition to illustrating the substantial traction of the sharing economy.

As we emphasized in our original introduction of Vaycaychella last week, Airbnb has the potential to be a global, seismic economic event spotlighting the unprecedented, and until now, largely untapped potential of the sharing economy. Airbnb has more rooms to rent (7 million) than the five largest hotel operators combined (4.3 million) – Marriott, Hilton, Intercontinental Wyndham and Hyatt,

Further illustrating the potential of the sharing economy, DoorDash is also expected to IPO before the end of the year at a $25 billion valuation. DoorDash harnesses the energy of an entrepreneurial, on demand work force and their private transportation resources to provide the world’s largest third-party delivery service that is now rivaling Fed-Ex.

Sharing economy technology enable enterprises like Airbnb and DoorDash and, with great expectations, Vaycaychella, empower anyone and everyone around the world to combine their personal resources (homes, cars, savings and talent for example) under a single organized business, that can compete with if not dominate any traditional Fortune 500 competitor.

Last week on Friday, Vaycacychella migrated its P2P app out of development and into testing. After completing internal testing, we will begin beta testing. Later this week, Vaycaychella plans to start signing up beta users to begin testing the P2P app before the end of the month.  Management expects a production launch of the P2P app before year-end.

To learn more and keep up with the latest updates, visit https://www.vaycaychella.com/. At the company website, you will find a blog with frequent industry publications on the short-term rental market in general, as well as entries specific to Vaycaychella.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

WSGF Contact:

William “Bill” Justice
[email protected] 
(800) 871-0376

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/wsgf–vaycaychella-completes-p2p-app-for-the-sharing-economy-sector-expected-to-see-50-billion-in-ipos-by-year-end-between-airbnb-and-doordash-301174344.html

SOURCE World Series of Golf, Inc.

WASHINGTON, Nov. 17, 2020 /PRNewswire/ — Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: EXAS), Foundation Medicine, Illumina (NASDAQ: ILMN), LabCorp (NYSE: LH), QIAGEN (NYSE: QGEN), Roche Diagnostics (SIX: RO, ROG: OTCQX: RHHBY), and Thermo Fisher Scientific (NYSE: TMO).

CGP testing performed soon after a diagnosis of advanced cancer better informs medical management, including treatment decisions and patient care, which can improve clinical outcomes. In advocating for coverage of CGP, ACGP will educate health insurers and other healthcare stakeholders about the clinical utility and economic value of CGP.

CGP tests assess the genomic alterations within a patient’s cancer to help physicians make more informed decisions about personalized treatment approaches. Using next-generation sequencing (NGS) with a tissue biopsy or a blood sample, this testing method can detect the four main classes of alterations known to drive cancer growth: base substitutions, insertions and deletions, copy number alterations (CNAs), and rearrangements or fusions. These tests can reveal clinically relevant alterations and biomarkers in the tumor’s DNA and RNA. This helps identify patients who could respond to specific targeted therapies and immunotherapy that can be more effective and may have fewer side effects. Healthcare professionals can use CGP to help predict patient benefit across multiple targeted therapies and cancer indications, with benefits in progression-free survival for patients with non-small cell lung cancer (NSCLC) as one example.¹

“Cancer is a disease of the genome, not solely the tissue. Tumor profiling has evolved tremendously in the last decade,” said Jim Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp, and the chairman of ACGP. “The manufacturers and laboratories forming the coalition have produced incredible assays to help identify the mutations driving advanced cancers, leading patients to better care through targeted cancer treatments.” 

Despite evidence of the benefits of this approach, some health insurers still use an outdated framework to evaluate coverage for CGP, creating a disparity in access across patient populations. Many commercial insurance plans do not cover this type of testing, while public or government plans like Medicare do. Limited insurance coverage options may prevent some treating physicians from ordering CGP for their patients.

“There is no question that obstacles to coverage have inhibited physicians from ordering comprehensive genomic profiling,” said Almas. “Additionally, we believe some clinicians are not aware of the advantages of a comprehensive testing approach and the benefits of one CGP test to provide genomic profiling, detect microsatellite instability and tumor mutational burden, and help physicians identify clinical trials for which patients may be candidates.”

To learn more about ACGP, go to www.accesstoCGP.com

1: Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. 2019;321(14):1391-1399.

View original content:http://www.prnewswire.com/news-releases/leading-diagnostics-companies-join-forces-to-establish-the-access-to-comprehensive-genomic-profiling-coalition-acgp-301173029.html

SOURCE Access to Comprehensive Genomic Profiling

PARIS, Nov. 17, 2020 /PRNewswire/ — Artprice’s quarterly Global Art Market Index normally shows seasonal fluctuations and, in the longer run, has shown a slight contraction since 2016. In 2020, despite the health crisis, the trend has continued unperturbed without any visible drop. 

Artprice’s latest updated global art price indices (segmented by category, period and country) are available free of charge at: https://imgpublic.artprice.com/pdf/agi.xls?ts=2020-11-17 10:19:15

Don’t hesitate to contact our Econometrics Department for your requirements regarding statistics and personalized studies: [email protected]

We would expect to see some sort of latent price correction, but it will probably not become visible until after a return to ‘normal’ trading. In times of crisis, the Art Market slows down its supply by raising the qualitative selectivity of lots offered to avoid disappointments and maintain price levels. This year, the lockdowns took effect before auction houses had time to react, forcing an abrupt halt to transactions and then subsequently slowing their recovery.

“The Art Market has its own defense mechanisms“, says thierry Ehrmann, President and Founder of Artmarket.com and its Artprice department. “The real price impact of the health crisis will not be fully visible until the auction market returns to a normal volume of trade (500,000 lots sold at auctions per year) and, above all, until private sales have successfully established enough new channels to offset the absence of major fairs and the closure of so many galleries. For the time being, we are pleased to note that the secondaryart market is finding the necessary resources in terms of the numbers of lots offered, technical solutions and financial liquidity to ensure a decent level of activity.“

Artprice calculates its Global Art Market Indices on the basis of the results obtained at public sales exclusively. However, this segment of the market appears to have adapted more quicky and successfully to lockdown measures: from the beginning of the year to the end of October, global art auction turnover contracted by only -25% versus FY 2019 with the number of lots sold falling only -16%. Auction houses have therefore managed to continue with the bulk of their operations, which is not the case for lots of galleries and art fairs.

Several auction records have also proved that art market prices have by no means been systematically undermined. On the contrary, they have remained relatively robust this year. The sale of Giorgio de Chirico’s painting Il pomeriggio di Arianna (1913) for $15.9 million at Sotheby’s in New York on 29 October 2020 illustrates a market still keen to acquire masterpieces. The sale of Boticelli’s Young Man Holding a Roundel has been postponed  until January. Auction houses may be delaying some sales, but they are ensuring the continuity of transactions. 

Image: [https://imgpublic.artprice.com/img/wp/sites/11/2020/11/ARTMARKET-artprice-global-index-Indices-2020-nov.png]

Copyright 1987-2020 thierry Ehrmann

www.artprice.com

–

www.artmarket.com

Try our services (free demo): https://www.artprice.com/demo

Subscribe to our services: https://www.artprice.com/subscription

About Artmarket:

Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Discover Artmarket and its Artprice department on video: https://en.artprice.com/video

Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.

See certified biography in Who’s who ©:

https://imgpublic.artprice.com/img/wp/sites/11/2019/10/biographie_oct2019_WhosWho_thierryEhrmann.pdf

Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 740,000 artists.

Artprice Images® allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.

Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 4.5 million ‘members log in’ users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace® to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France’s Commercial Code).

Artmarket with its Artprice department, has been awarded the State label “Innovative Company” by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.

Artprice by Artmarket’s 2019 Global Art Market Report published in February 2020 :

https://www.artprice.com/artprice-reports/the-art-market-in-2019

Index of press releases posted by Artmarket with its Artprice department:

http://serveur.serveur.com/press_release/pressreleaseen.htm

Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:

https://www.facebook.com/artpricedotcom/ (4.9 million followers)

https://twitter.com/artmarketdotcom

https://twitter.com/artpricedotcom

Discover the alchemy and universe of Artmarket and its artprice department http://web.artprice.com/video headquartered at the famous Organe Contemporary Art Museum “The Abode of Chaos” (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013

L’Obs – The Museum of the Future: https://youtu.be/29LXBPJrs-o

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999

(4.5 million followers)

https://vimeo.com/124643720

Contact Artmarket.com and its Artprice department – Contact: thierry Ehrmann, [email protected]

Photo – https://mma.prnewswire.com/media/1336516/Artprice_Global_Index.jpg  
Logo – https://mma.prnewswire.com/media/1009603/Art_Market_logo.jpg

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/artprice-indices-art-values-are-holding-up-301174641.html

SOURCE Artmarket.com

CEDAR KNOLLS, N.J., Nov. 17, 2020 /PRNewswire/ — MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS)

As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corporation (“MYOS”), and MedAvail, Inc., a privately-held Delaware corporation (“MedAvail”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among MYOS, MedAvail, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS (“Merger Sub”), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into MedAvail, with MedAvail being the surviving corporation and a wholly-owned subsidiary of MYOS (the “Merger”). In addition, prior to the Merger, MYOS will contribute substantially all its assets and liabilities to a wholly owned subsidiary, MYOS Corp., a Delaware corporation (“MYOS Corp.”) in exchange for all the outstanding shares of common stock of MYOS Corp., and, the day following the Merger, MYOS shall dividend the shares of stock of MYOS Corp. to MYOS’s shareholders existing as of the October 2, 2020 record date, as a result of which MYOS Corp. will continue the existing business of MYOS as a private company.

At the special meeting of the shareholders held on November 16, 2020 (the “Special Meeting”), the MYOS shareholders approved, among other matters, (i) a reverse stock split at a ratio within a range of one share of MYOS Common Stock for every two to fifteen shares of MYOS Common Stock outstanding (or any number in between) (the “Reverse Stock Split”), the exact ratio within the two to fifteen range to be determined by the Board of Directors of MYOS (the “MYOS Board”) prior to the Effective Time and publicly announced by MYOS, and (ii) the amendment of the Nevada articles of incorporation to effect the Reverse Stock Split.

On November 16, 2020 and following the Special Meeting, the MYOS Board of Directors approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding. 

Additional Information and Where to Find It

MYOS has filed with the Securities and Exchange Commission (“SEC”), and the parties have furnished to the security holders of MYOS and MedAvail, a Registration Statement on Form S-4 (“Form S-4”), which was declared effective by the SEC on October 15, 2020, which also constituted a proxy statement/prospectus/information statement of MYOS and included an information statement of MedAvail in connection with the proposed Merger. The Proxy Statement/Prospectus/Information Statement described above contains important information about MYOS, MedAvail, the proposed Merger and related matters. Investors are urged to read the Proxy Statement/Prospectus/Information Statement carefully. Investors will be able to obtain free copies of these documents, and other documents filed with the SEC by MYOS, through the website maintained by the SEC at www.sec.gov. In addition, investors will be able to obtain free copies of these documents from MYOS by going to MYOS’s Investor Relations web page at https://ir.myosrens.com/ and clicking on the link titled “SEC Filings” or by contacting MYOS’s Investor Relations group at 973-509-0444 or [email protected].

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 

Participants in the Solicitation

The respective directors and executive officers of MYOS and MedAvail may be deemed to be participants in the solicitation of proxies from the shareholders of MYOS and written consent of the stockholders of MedAvail in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the proposed Merger will be included in the Proxy Statement/Prospectus/Information Statement described above. Additional information regarding MYOS’s directors and executive officers is included in MYOS’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 24, 2020, and in MYOS’s proxy statement for its 2019 Annual Meeting of Stockholders, which was filed with the SEC on December 5, 2019. These documents are available from MYOS free of charge as described above.

About MYOS RENS Technology, Inc.

MYOS RENS Technology Inc. (MYOS), “The Muscle Company®”, is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness and produces muscle health support products featuring Fortetropin under the names of Yolked®, Physician Muscle Health Formula®, MYOS Canine Muscle Formula®, (Regular & Vet Strength) and Qurr®. For more information, please visit www.myosrens.com.

Forward Looking Statements

This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. MYOS’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the ability of MYOS to timely and successfully achieve the anticipated benefits of the Merger. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in the Form S-4 and elsewhere in MYOS’s most recent filings with the SEC, including MYOS’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on MYOS’s Investor Relations page at https://ir.myosrens.com/ by clicking on the link titled “SEC Filings.” The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts MYOS’s and MedAvail’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

The forward-looking statements included in this communication are made only as of the date hereof. MYOS and MedAvail assume no obligation and do not intend to update these forward-looking statements, except as required by law.

Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: [email protected]

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-board-of-directors-approved-the-reverse-stock-split-ratio-of-one-new-share-for-every-12-shares-of-common-stock-outstanding-301174273.html

SOURCE MYOS RENS Technology

SOUTH PLAINFIELD, N.J., Nov. 17, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC’s splicing platform and is being developed for the treatment of Huntington’s disease (HD). PTC518 is an orally bioavailable molecule with broad central nervous system and systemic distribution and has been designed to target Huntingtin protein expression with high selectivity and specificity. PTC518 has favorable pharmaceutical properties and has demonstrated uniform lowering of the Huntingtin protein throughout the brain in animal models. Currently there are no approved disease modifying therapies for HD.

“The initiation of the clinical trial to evaluate PTC518 for the Huntington’s disease program is an important milestone towards identifying a potential new Huntington’s disease treatment that directly targets the underlying cause of the disease,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. “PTC518 is the only orally bioavailable small molecule therapeutic that was identified to selectively and specifically modulate Huntington’s disease splicing to reduce huntingtin protein. Analogous to the SMA drug from our splicing platform, this trial is anticipated to establish the appropriate PTC518 dose that reduces HTT protein levels. We believe that the convenient oral administration of PTC518 has the potential to change the treatment landscape for these patients.”

The Phase 1 study includes both single and multiple ascending dosing regimens that will help establish the safety, pharmacology, and dose selection for the Phase 2 study. In addition, huntingtin mRNA and protein levels will be measured to gain early proof of splicing mechanism in humans as was done in the risdiplam SMA development program. Data from the Phase 1 study are expected to be available in the first half of 2021.

About PTC518

PTC518 is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering HTT mRNA degradation and subsequent reduction in HTT protein levels. In preclinical studies using cells isolated from patients with Huntington’s disease (HD), PTC518 reduced both huntingtin mRNA and protein levels with high potency in a dose-dependent manner. In addition, oral administration of PTC518 in the BACHD mouse model of HD achieved dose dependent and equitable lowering of HTT protein throughout the body, including the brain, muscle, and blood.

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

Media:

Jane Baj

+1 (908) 912-9167
[email protected]  

Investors:

Lisa Hayes

+1 (732) 354 8687
[email protected] 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; PTC’s strategy, future operations, future financial position, future revenues and projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC’s products or product candidates that PTC commercializes or may commercialize in the future; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC’s scientific approach and general development progress; and the factors discussed in the “Risk Factors” section of PTC’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-that-ptc518-has-entered-into-a-phase-1-clinical-trial-for-the-huntingtons-disease-program-301174225.html

SOURCE PTC Therapeutics, Inc.

NEW BRUNSWICK, N.J., Nov. 17, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. Society has been significantly impacted by systemic racism, the COVID-19 pandemic, and the economic decline throughout this year, which have all spotlighted healthcare inequities.

“There is an urgent need to take on the inequities rooted in systemic racism that threaten health in communities of color across the United States,” said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson. “That’s why Johnson & Johnson is focusing its efforts and committing $100 million to address racial and social injustice as the critical public health issue that it is. As the largest and most broadly-based healthcare company in the world, we are uniquely positioned to convene private, public and community organizations in pursuit of this shared aspiration—and work together to make a meaningful impact through science, business, public health, and philanthropy.”

The Company’s commitment prioritizes three key areas: Healthier Communities – investing in programs that help provide equitable healthcare for underserved communities; Enduring Alliances – forging partnerships and alliances that combat racial and social health determinants; and Diverse & Inclusive Corporate Culture – ensuring a diverse and inclusive workforce.

Healthier Communities

“The quality of your healthcare should not be determined by your race and ethnicity,” said Alex Gorsky. Johnson & Johnson is investing in culturally competent community care solutions that create healthier outcomes for Black people and other communities of color. Several key community programs are immediately underway, and others will be deployed.

• In order to better connect clinical and medical care with social and cultural needs, Johnson & Johnson is introducing new scholarships, mentoring and non-financial support to improve representation of people of color in medical, scientific, and health professions.
• The Company will strengthen community health by providing technology enhancements and mobile health solutions, that put health within reach of underserved and minority populations through partnerships with Community Based Clinics and Federally Qualified Health Centers.
• Johnson & Johnson is undertaking a major initiative to increase access and participation in clinical trials in diverse populations.
• While health equity efforts will go beyond the COVID-19 pandemic, knowing communities of color have been disproportionally impacted, the Company has funded mobile vans to extend the reach of care in high-need and hard-to-reach areas to support COVID-19 testing, starting with Detroit and New Orleans. Further, the Company is seeking diverse enrollment in the COVID-19 vaccine clinical trials to inform the safety and effectiveness of the vaccine.
• As a kick-start effort to bring health equity ideas forward directly from those impacted, Johnson & Johnson will partner with local community leaders, businesses and entrepreneurs in six major cities across America to identify and invest in scalable and sustainable healthcare solutions that have the potential to create a positive impact for communities of color.

Enduring Alliances

“Our 130+ year history in healthcare, science and technology gives us access to a global network that we will activate and inspire to join us in influencing systemic change that positively impacts the quality of healthcare for Black people and other communities of color,” said Michael Sneed, Executive Vice President, Global Corporate Affairs & Chief Communications Officer, Johnson & Johnson.

Johnson & Johnson is leveraging its global network to also address social, environmental, and economic determinants related to health inequities. The Company is partnering with universities, health systems, NGOs and governments to build breakthrough coalitions to develop and expand economic, education and social programs that close the health disparity divide.

• Starting in 2021, the Company will introduce alliances, collaborations and partnerships that support health equity solutions and educational programming ranging from maternal health resources to inspiring black students to pursue science and health careers.
• Johnson & Johnson is partnering with The Executive Leadership Council to provide college scholarships and other resources to Black students who have a passion for STEM, business, or healthcare-related fields.
• The Company will invest in partnerships that address the disproportionate health impact of climate change on communities of color.

In addition to its commitment to health equity, through the Johnson & Johnson Supply Chain, the Company is also proud to commit several hundred million in annual spend with Black and Hispanic owned businesses over the next five years to drive positive social and economic impact.

Diverse & Inclusive Corporate Culture

“Our long-standing commitment to diversity, equity, and inclusion gives us the foundation to drive sustainable change. We are accelerating and expanding our efforts to strengthen our inclusive culture and build a workforce that reflects the diversity of the patients and communities we serve.” said Wanda Hope, Chief Diversity & Inclusion Officer, Johnson & Johnson.

Internally, Johnson & Johnson remains focused on cultivating a diverse and inclusive workforce that inspires innovative healthcare solutions around the world.

• The Company is committed to hiring more diverse employees and has set a goal of achieving 50% growth of its African American talent at the manager and above levels in the U.S. over the next five years.
• Johnson & Johnson is also enhancing HR processes to optimize how it accesses, hires, and develops talent, and is offering cultural immersion programs to enhance awareness and understanding.

Johnson & Johnson will make multi-million-dollar investments in Healthier Communities and Enduring Alliances programs, while the investment made in its Diverse & Inclusive Corporate Culture will largely focus on enhancing processes, training, and education. Although this announcement represents immediate action, Johnson & Johnson’s commitment to address racial and social injustice is enduring.

ABOUT JOHNSON & JOHNSON

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Note to Investors Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of The Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in The Company’s most recently filed Quarterly Report on Form 10-Q, and The Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson–johnson-to-address-racial-and-social-injustice-through-platform-that-aims-to-eliminate-health-inequities-for-people-of-color-301174429.html

SOURCE Johnson & Johnson

MINNEAPOLIS, Nov. 17, 2020 /PRNewswire/ —

 

 

 

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/target-corporation-to-webcast-3rd-quarter-earnings-conference-call-on-wednesday-november-18-2020-301174425.html

SOURCE Target Corporation

VANCOUVER, BC, Nov. 17, 2020 /PRNewswire/ – Eclipse Gold Mining Corporation (“Eclipse” or the “Company“) (TSXV: EGLD) (USOTC: EGLPF) is pleased to announce that it, together with the Company’s wholly-owned subsidiary, Hercules Gold USA LLC (“Hercules“), has entered into a binding purchase and sale agreement (the “Purchase Agreement“) with CP Holdings Corporation, a wholly owned subsidiary of Headwater Gold Inc. (the “Sellers“) to acquire a 100% interest in 83 unpatented lode mining claims situated internal and adjacent to Eclipse’s Hercules Project (the “Mining Claims“) as well as a historical dataset of 88 drillholes, 628 rock samples, 1578 soil samples and other geological data (the “Dataset“).    

Subject to TSX Venture approval, Eclipse will acquire an undivided 100% interest in the Mining Claims and Dataset by:

• Making a one-time payment of US$100,000
• Issuing 500,000 common shares of the Company to the Sellers
• Granting a net smelter royalty to the Seller that varies between 1.25% and 2.5% on the Mining Claims (the “NSR”)

Eclipse has reserved the right to buy 50% of the NSR, and a right of first refusal on the remainder.

About Eclipse Gold Mining

Eclipse Gold Mining is exploring the district-scale Hercules gold property within Nevada’sWalker Lane trend. The Hercules property is located only a one-hour drive from Reno and appears to have all the characteristics of a large, low-sulphidation epithermal gold system. The Company brings together a team with a track record of nine successful buyouts/exits totaling $4.6 billion.

ON BEHALF OF THE BOARD OF DIRECTORS

Michael G. Allen

President, CEO and Director

TSXV: EGLD | OTC:EGLPF | Frankfurt:43J | ISIN: CA27888R1001 | WKN: A2PYV4

Cautionary statements

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

View original content:http://www.prnewswire.com/news-releases/eclipse-further-expands-hercules-gold-project-in-nevadas-walker-lane-trend-301174397.html

SOURCE Eclipse Gold Mining Corporation

THE FIRST OF ITS KIND, RECIPE CREATES RESTAURANT BRAND MARKETPLACE, FULLY INTEGRATING THE OPERATIONS OF SWISS CHALET, NEW YORK FRIES, HARVEY’S, EAST SIDE MARIO’S, MONTANA’S BBQ AND PARTNER CONCEPTS FRESH, BENTO SUSHI AND BLONDIES PIZZA. 8 GREAT BRANDS TO ENJOY INDIVIDUALLY OR TOGETHER IN ONE ORDER.

VAUGHAN, ON, Nov. 17, 2020 /CNW/ – Today, Recipe Unlimited, Canada’s largest full-service restaurant company, formally announced the launch of its second multi-branded takeout and delivery focused concept restaurant, Ultimate Kitchens. The company opened its first location in March 2020.  The new location, set to open next week, will feature a fully integrated digital Guest takeout and delivery experience.  The participating brands across the two locations include a combination of Swiss Chalet, New York Fries, Harvey’s, East Side Mario’s, Montana’s BBQ and partner concepts Fresh, Bento Sushi and Blondies Pizza. Focused on expanding its offering and strategically partnering with third-party concepts to fill cuisine needs, Ultimate Kitchens will provide Guests with access to a variety of concepts underserviced or not available in their local neighbourhood.

“Ultimate Kitchens brings our iconic brands, partner concepts and new cuisines to the homes of more Canadians while providing Guests with a one-stop dining marketplace, combining meal variety, quality, value and speed in a single, effortless order.  Our new prototype creates a fully digital takeout ordering experience, adding a new channel for Guests to conveniently pick up food faster than what they’re accustomed to. Takeout or delivery, you can either enjoy the brands individually or mix and match to get exactly what you want in a single order” says Frank Hennessey, CEO, Recipe Unlimited.

“This concept represents a significant opportunity for future growth and expansion for Recipe in Canada and beyond our borders.  It’s on-point with the shift in consumer behaviour while enabling Recipe to serve markets where it may otherwise be cost prohibitive to build a traditional restaurant. The focus on takeout and delivery will enable us to better serve our Guests in these communities” said Hennessey. The Company intends to have a national presence with as many as 12 locations by the end of 2021.

The multi-branded Ultimate Kitchens concept is exclusively offered on DoorDash, a leading last-mile logistics platform, for a limited period of time. The two companies teamed up earlier this year in a national partnership to bring Recipe’s brand favorites to customers’ doorsteps. Recipe chose DoorDash as the exclusive delivery platform partner of Ultimate Kitchens because of their shared commitment to operational excellence and strong partnership values.

“We’re proud to have been chosen as the exclusive delivery platform for Recipe’s multi-branded delivery concept. A strong off-premises strategy is a critical component to the success of any virtual concept, and given our history building and operating similar concepts for restaurant partners in the US, we’re excited to bring our insights to this project and enhance Ultimate Kitchens’ delivery-only operations,” said Tom Pickett, Chief Revenue Officer at DoorDash.

Starting November 23^rd, through the end of the year, Guests can get 20% off orders of $15 or more from the Ultimate Kitchens DoorDash store*.  Both Recipe and DoorDash are committed to the safety and health of customers, employees, Dashers and community, and all orders will be delivered with contactless delivery for the foreseeable future.  To place an order today, visit the DoorDash app for iOS and Android or online on the DoorDash website.

*Offer valid through 12/31/2020. Valid only on orders with a minimum subtotal greater than $15, excluding taxes and fees, with a max discount up to $25. Limit 3 redemptions per person. Not valid for the purchase of alcohol. Fees, taxes, and gratuity still apply. All deliveries subject to availability. Must have or create a valid DoorDash account with a valid form of accepted payment on file. No cash value. Non-transferable. No code necessary. See full terms and conditions at help.doordash.com/consumers/s/article/offer-terms-conditions.

About Recipe

Founded in 1883, Recipe Unlimited Corporation is Canada’s largest full-service restaurant company. The Company franchises and/or operates some of the most recognized brands in the country including Swiss Chalet, Harvey’s, St-Hubert, The Keg, Milestones, Montana’s, Kelseys, East Side Mario’s, New York Fries, Prime Pubs, Bier Markt, Landing, Original Joe’s, State & Main, Elephant & Castle, The Burger’s Priest, The Pickle Barrel, Marigolds & Onions, and 1909 Taverne Moderne.

RECIPE’s iconic brands have established the organization as a nationally recognized franchisor of choice. As at September 27, 2020, Recipe had 24 brands and 1,355 restaurants, 84% of which are operated by franchisees and joint venture partners, operating in 10 countries (Canada, USA, Bahrain, China, India, Macao, Oman, Panama, Saudi Arabia and the UAE).  RECIPE’s shares trade on the Toronto Stock Exchange under the ticker symbol RECP. More information about the Company is available at www.recipeunlimited.com.

About DoorDash

DoorDash is a technology company that connects customers with their favorite local and national businesses in more than 4,000 cities and all 50 states across the United States, Canada, and Australia. Founded in 2013, DoorDash empowers merchants to grow their businesses by helping to solve mission-critical challenges, such as customer acquisition, on-demand delivery, insights and analytics, merchandising, payment processing, and customer support. By building the last-mile delivery logistics platform for local cities, DoorDash is bringing communities closer, one doorstep at a time. Read more on the DoorDash blog or at www.doordash.com.

For further information, contact:

Yianni Fountas | Recipe Unlimited, Sr. Director | Emerging Brands & Partnerships, Strategic Projects and Business Insights, E: [email protected]

Cat McCormack | DoorDash, Communications, E: [email protected]

SOURCE Recipe Unlimited Corp.